Overall, we found that both the NF-κB/PAX7-related muscle inflammation and C26-induced splenomegaly were restrained by PM01183 for as long as the treatment lasted, with no change in the plasma levels of the main inflammatory cytokines, such as IL-6, IL-1β and macrophage colony-stimulating factor (M-CSF). The gene discussed is CSF1; the disease is Splenomegaly.